Clinical Trial Update: A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3 [Phase 2]

View source ↗

Summary

A randomized Phase II study evaluating two doses of interferon alfa-2a plus AZT and ddC versus AZT and ddC alone in HIV patients with CD4 counts <400.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• AZT (zidovudine)
• Interferon alfa-2a (interferon alfa-2a)
• ddC (dideoxycytidine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED